Zimmer Biomet (ZBH) PT Lowered to $145 at JMP Securities

JMP Securities lowered its price target on Zimmer Biomet (NYSE: ZBH) to $145.00 (from $150.00) while maintaining a Market Outperform rating.

Analyst David Turkaly cuts the PT after a downward adjustment to his modeled EPS. He remains positive on the equity noting the price is inexpensive relative to peers and believes the board will be able to locate a quality candidate for the CEO role that would alleviate the challenges the company currently faces.

You May Also Be Interested In

• Ooma (OOMA) PT Raised to $24 at Freedom Broker
• Veeva Systems (VEEV) PT Raised to $305 at Truist Securities
• Dick's Sporting Goods (DKS) PT Lowered to $130 at Williams Trading